{"id":2194,"date":"2020-06-14T22:05:46","date_gmt":"2020-06-15T02:05:46","guid":{"rendered":"https:\/\/ecademydj.com\/?p=2194"},"modified":"2020-06-14T22:05:46","modified_gmt":"2020-06-15T02:05:46","slug":"from-biotech-to-big-pharma","status":"publish","type":"post","link":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/","title":{"rendered":"From biotech to Big Pharma?"},"content":{"rendered":"

By Dominique Jacquet<\/h3>\n

\"\"<\/p>\n

We have already mentioned the strategic nature and the complexity of the so-called \u2018make or buy?\u2019 decision, which consists of manufacturing vs. subcontracting.<\/p>\n

 <\/p>\n

In the case of biotechnology companies, it would seem that the question does not arise, because these companies develop drugs to carry them in phase 1 or 2, often with the financial support of the large pharmaceutical companies, then are bought by these same firms if successful.<\/p>\n

 <\/p>\n

This was the case with Pharmasset, acquired by Gilead in 2012 and which was the subject of our vidcast in May.<\/p>\n

 <\/p>\n

In complete contradiction with this observation, Moderna has the clear ambition of retaining its independence, eventually developing its own manufacturing footprint.<\/p>\n

 <\/p>\n

\u2018mRNA, the software of life\u2019<\/em><\/strong><\/p>\n

Jacques Monod and Fran\u00e7ois Jacob received the Nobel Prize for Medicine in 1965 by emitting and developing the concept of messenger RNA which allows, by simplifying (see Wikipedia for technical explanations<\/a>!), the cell to regulate the expression of different proteins including she needs. This is genetic coding, hence the expression used by Moderna, the software of life.<\/p>\n

 <\/p>\n

The company is developing vaccines based on this technology and is very advanced in the development of a vaccine against COVID-19, which obviously places it at the heart of media and financial activity.<\/p>\n

 <\/p>\n

Founded in 2010, Moderna entered Nasdaq in 2018 under the symbol MRNA, its trademark, and the first months of its listing showed ups and downs around Nasdaq index.<\/p>\n

 <\/p>\n

The following graph shows the evolution of the firm’s revenues and profits over 4 years. Having no FDA approval (yet), revenues consist only of advances from partnerships signed with large pharmaceutical companies.<\/p>\n

\"\"<\/p>\n

Source Yahoo Finance<\/strong><\/p>\n

 <\/p>\n

At the end of February 2020, it achieved a cumulative performance identical to its benchmark with a price of $ 18.6, then began an exceptional stock market rally which brought it to $ 86 on May 18 due to very promising announcements on the development of the vaccine against novel coronavirus<\/em>. So, the firm, although having cash of nearly 1.7 billion US dollars (source: Q1 2020), issues new shares at a price of $ 76 to raise 1.25 billion dollars bringing its cash to about 3 billion. The announced objective is not to finance research, which consumes 500 million dollars per year, but to actually build an industrial footprint which, in complement with an industrial partnership agreement with the Swiss company Lonza, will make it possible to produce, according to the words of its CEO St\u00e9phane Bancel, up to a billion doses per year.<\/p>\n

 <\/p>\n

The first production batches will be launched by Lonza in July 2020, while (announcement of June 11) the phase 3 study (in fast track) with 30,000 subjects will only start this same month … This represents a \u2018significant\u2019 industrial risk and shows considerable confidence on the part of the various players in the scientific and industrial success of the project.<\/p>\n

 <\/p>\n

On May 27, the price fell sharply and closed at $ 51\u2026 before rising to $ 62 on June 12. The (near) future will tell us if we are observing an occurrence, among others, of an emotional stock market boom or the birth of an important player in the pharmaceutical world with the arrival of a new CFO , David Meline, ex-Executive Vice-President & CFO of Amgen.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

By Dominique Jacquet We have already mentioned the strategic nature and the complexity of the so-called…<\/p>\n","protected":false},"author":2,"featured_media":2192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nFrom biotech to Big Pharma? - Ecademy Dominique Jacquet<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From biotech to Big Pharma?\" \/>\n<meta property=\"og:description\" content=\"By Dominique Jacquet We have already mentioned the strategic nature and the complexity of the so-called…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Ecademy Dominique Jacquet\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-15T02:05:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marc Desjardins\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marc Desjardins\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/\"},\"author\":{\"name\":\"Marc Desjardins\",\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#\\\/schema\\\/person\\\/1893bb41d192a8b07bf39a5fae101cc0\"},\"headline\":\"From biotech to Big Pharma?\",\"datePublished\":\"2020-06-15T02:05:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/\"},\"wordCount\":531,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/\",\"url\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/\",\"name\":\"From biotech to Big Pharma? - Ecademy Dominique Jacquet\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg\",\"datePublished\":\"2020-06-15T02:05:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg\",\"contentUrl\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg\",\"width\":800,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/2020\\\/06\\\/14\\\/from-biotech-to-big-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"From biotech to Big Pharma?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/\",\"name\":\"Ecademy Dominique Jacquet\",\"description\":\"Cr\u00e9ation de formations num\u00e9riques corporatives en finances contemporaines\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#organization\",\"name\":\"E-Cademy Dominique Jacquet\",\"url\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/newisolatedlogodj1b.jpg\",\"contentUrl\":\"https:\\\/\\\/ecademydj.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/newisolatedlogodj1b.jpg\",\"width\":924,\"height\":254,\"caption\":\"E-Cademy Dominique Jacquet\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/e-cademy-dominique-jacquet\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ecademydj.com\\\/en\\\/#\\\/schema\\\/person\\\/1893bb41d192a8b07bf39a5fae101cc0\",\"name\":\"Marc Desjardins\",\"url\":\"https:\\\/\\\/ecademydj.com\\\/en\\\/author\\\/mdesjardins\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"From biotech to Big Pharma? - Ecademy Dominique Jacquet","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/","og_locale":"en_US","og_type":"article","og_title":"From biotech to Big Pharma?","og_description":"By Dominique Jacquet We have already mentioned the strategic nature and the complexity of the so-called…","og_url":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/","og_site_name":"Ecademy Dominique Jacquet","article_published_time":"2020-06-15T02:05:46+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg","type":"image\/jpeg"}],"author":"Marc Desjardins","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marc Desjardins","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#article","isPartOf":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/"},"author":{"name":"Marc Desjardins","@id":"https:\/\/www.ecademydj.com\/en\/#\/schema\/person\/1893bb41d192a8b07bf39a5fae101cc0"},"headline":"From biotech to Big Pharma?","datePublished":"2020-06-15T02:05:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/"},"wordCount":531,"commentCount":0,"publisher":{"@id":"https:\/\/www.ecademydj.com\/en\/#organization"},"image":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/","url":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/","name":"From biotech to Big Pharma? - Ecademy Dominique Jacquet","isPartOf":{"@id":"https:\/\/www.ecademydj.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#primaryimage"},"image":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg","datePublished":"2020-06-15T02:05:46+00:00","breadcrumb":{"@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#primaryimage","url":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg","contentUrl":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/06\/Image-1-Moderna-Therapeutics-Clinical-Manufacturing-Facility.jpg","width":800,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/ecademydj.com\/en\/2020\/06\/14\/from-biotech-to-big-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ecademydj.com\/en\/"},{"@type":"ListItem","position":2,"name":"From biotech to Big Pharma?"}]},{"@type":"WebSite","@id":"https:\/\/www.ecademydj.com\/en\/#website","url":"https:\/\/www.ecademydj.com\/en\/","name":"Ecademy Dominique Jacquet","description":"Cr\u00e9ation de formations num\u00e9riques corporatives en finances contemporaines","publisher":{"@id":"https:\/\/www.ecademydj.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ecademydj.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ecademydj.com\/en\/#organization","name":"E-Cademy Dominique Jacquet","url":"https:\/\/www.ecademydj.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ecademydj.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/01\/newisolatedlogodj1b.jpg","contentUrl":"https:\/\/ecademydj.com\/wp-content\/uploads\/2020\/01\/newisolatedlogodj1b.jpg","width":924,"height":254,"caption":"E-Cademy Dominique Jacquet"},"image":{"@id":"https:\/\/www.ecademydj.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/e-cademy-dominique-jacquet\/"]},{"@type":"Person","@id":"https:\/\/www.ecademydj.com\/en\/#\/schema\/person\/1893bb41d192a8b07bf39a5fae101cc0","name":"Marc Desjardins","url":"https:\/\/ecademydj.com\/en\/author\/mdesjardins\/"}]}},"_links":{"self":[{"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/posts\/2194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/comments?post=2194"}],"version-history":[{"count":0,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/posts\/2194\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/media\/2192"}],"wp:attachment":[{"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/media?parent=2194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/categories?post=2194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ecademydj.com\/en\/wp-json\/wp\/v2\/tags?post=2194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}